- PAHL 4834
- PAHL 3808
Byram W. Bridle
Assistant Professor | PhD
I am a viral immunologist who is passionate about improving life through two avenues of research. First, my research team is dedicated to designing and optimizing novel biotherapies for the treatment of cancers. Our goal is to harness the natural power of a patient's immune system to eliminate their own cancer cells. This represents the ultimate personalized therapy and holds the potential to treat cancers more effectively, safely, and at lower cost than current options. We also work on discovering mechanisms underlying cytokine responses to viruses and other inflammatory stimuli and how these differ between males and females. This has implications for the treatment of infectious diseases and understanding sex biases in the incidence of inflammation-mediated disorders. Mentoring the next generation of Canadian scientists is a responsibility that I take very seriously. I also count it a privilege to teach students in the Doctor of Veterinary Medicine, graduate and undergraduate programs at the University of Guelph.
My research program has two arms. One is to develop novel, highly targeted biotherapies for the treatment of cancers. In an effort to kill malignant cells with minimal bystander damage to normal tissues, two approaches are combined: 1. cancer immunotherapy that directs the power of a patient’s immune system against their own tumour(s) and, 2. oncolytic virotherapy, which utilizes viruses that replicate in and kill only cancerous cells. The exquisite specificity, systemic targeting capability and short treatment windows of these therapies hold promise that cancer patients might be effectively treated with reduced side effects and at minimal cost. The goal is to translate the most promising iterations of these therapies into clinical trials in companion animals as a stepping stone towards testing in human patients. A second emphasis of the lab is the study of host responses to viruses. Specifically, efforts are being invested into understanding the mechanisms underlying virus-induced cytokine storms. We have identified a critical role of signaling through the type I interferon receptor in the negative regulation of an extensive network of cytokines. Notably, we have also discovered that cytokine responses to viruses are often very different between females and males and are seeking to understand why.
This lab seeks researchers who are collaborative, highly motivated, innovative, hard-working and want to have a significant impact in the field of viral immunology. An outstanding academic record, excellent writing and oral presentation skills and a collaborative approach are essential. Trainees will have an opportunity to gain valuable, hands-on research experience in a variety of areas. Learning the fundamental principles of immunology, cancer biology and virology is an emphasis. Applicants who are willing to work longer hours than average, are passionate about pursuing a career in research, are excellent communicators, punctual, autonomous and possess excellent technical skills will excel in this laboratory. In return, members can expect diligent mentorship, access to state-of-the-art research resources, with opportunities spanning the basic to translational research spectrum, giving them the resources needed to potentially publish in the highest impact scientific journals and placing the future of their research career in their own hands.
The Bridle lab is currently funded by:
- The Natural Sciences and Engineering Research Council of Canada (NSERC)
- The Terry Fox Research Institute
- National Centre of Excellence in Biotherapeutics for Cancer Treatment (BioCanRx)
- The Pet Trust Foundation
- The Smiling Blue Skies Cancer Fund
- Canadian Foundation for Innovation - John R. Evans Leaders Fund
- Ministry of Research and Innovation Ontario Research Fund - Research Infrastructure Program
The Bridle lab is part of the…
- Canadian Oncolytic Virus Consortium
- Network of Centre of Excellence in Biotherapies for Cancer Treatment (founding member)
- Canadian Society of Immunology
- Institute for Comparative Cancer Investigation
- Dog Osteosarcoma Group: Biomarkers Of Neoplasia (DOG BONe)
Current Graduate Students
- VETM*3080 Veterinary Physiology and Biochemistry (Head Instructor: Veterinary Immunology)
- VETM*3450 Principles of Disease in Veterinary Medicine (Immunology Review Lecture)
- BIOM*4150/6702 Cancer Biology (Tumour Immunology Unit)
- BIOM*6800 Gene Expression in Health and Disease (Lecture: “Identification of genes encoding tumour-associated antigens and their use in cancer vaccine design”)
- PABI*6104 Mechanisms of Disease (Lecture: “Oncolytic and Immunotherapies”)
- BIOM*4521/2 Research in Biomedical Sciences
- BIOM 4500 Research in Biomedical Sciences Literature Review
- HK*4371/2 Research in Human Biology and Nutritional Sciences
- TOX*4900/10 Research Project
- PABI*6960 Special Topics in Pathobiology
Mould RC, van Vloten JP, AuYeung AWK, Karimi K, Bridle BW. Immune response in the thyroid cancer microenvironment: making immunotherapy a possible mission. Endocrine Related Cancer 2017 Sep 14. pii: ERC-17-0316.
Mould RC, AuYeung AWK, van Vloten JP, Susta L, Mutsaers AJ, Petrik JJ, Wood GA, Wootton SK, Karimi K, Bridle BW. Enhancing Immune Responses to Cancer Vaccines Using Multi-Site Injections. Scientific Reports 2017 Aug 16;7(1):8322.
Allison KE, Coomber BL, Bridle BW. Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes. Immunology 2017 Oct;152(2):175-184.
Kozak RA, Hattin L, Biondi MJ, Corredor JC, Walsh S, Xue-Zhong M, Manuel J, McGilvray ID, Morgenstern J, Lusty E, Cherepanov V, McBey BA, Leishman D, Feld JJ, Bridle B, Nagy É. Replication and oncolytic activity of an avian orthoreovirus in human hepatocellular carcinoma cells. Viruses 2017 Apr 24;9(4). pii: E90.
Bridle BW, Nguyen A, Salem O, Zhang L, Koshy S, Clouthier D, Chen L, Pol J, Swift SL, Bowdish DM, Lichty BD, Bramson JL, Wan Y. Privileged antigen presentation in splenic B cell follicles maximizes T cell responses in prime-boost vaccination. Journal of Immunology 2016 Jun 1;196(11):4587-95.
Bridle BW, Clouthier D, Zhang L, Pol J, Chen L, Lichty BD, Bramson JL, Wan Y. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines. Oncoimmunology 2013 Aug 1;2(8):e26013.
Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, Capretta A, He R, Bramson JL, Bell JC, Lichty BD, Wan Y. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Molecular Therapy 2013 Apr;21(4):887-94.
Bridle BW. Neuroendocrine cancer vaccines in clinical trials. Expert Review of Vaccines 2011 Jun;10(6):811-23. Review.
Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, Brunellière J, Bramson JL, Lichty BD, Wan Y. Potentiating cancer immunotherapy using an oncolytic virus. Molecular Therapy 2010 Aug;18(8):1430-9.
Bridle BW, Li J, Jiang S, Chang R, Lichty BD, Bramson JL, Wan Y. Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen. Journal of Immunology 2010 Apr 15;184(8):4269-75.
Bridle BW, Hanson S, Lichty BD. Combining oncolytic virotherapy and tumour vaccination. Cytokine and Growth Factor Reviews 2010 Apr-Jun;21(2-3):143-8. Review.
Bridle BW, Boudreau JE, Lichty BD, Brunellière J, Stephenson K, Koshy S, Bramson JL, Wan Y. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Molecular Therapy 2009 Oct;17(10):1814-21.
Search PubMed for additional publications by Dr. Bridle.